Status:
COMPLETED
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or an...
Eligibility Criteria
Inclusion
- Postmenopausal women with hormone receptor-positive early breast cancer and a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation
Exclusion
- Inflammatory and/or metastatic breast cancer.
- Current or previous malignancy within previous 5 years (other than Breast cancer or adequately treated non-melanoma skin cancer or in-situ cervical cancer).
- History of bleeding diathesis.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00357110
Start Date
April 1 2006
End Date
October 1 2008
Last Update
December 21 2010
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Feldkirch, Austria
2
Research Site
Graz, Austria
3
Research Site
Innsbruck, Austria
4
Research Site
Klagenfurt, Austria